Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 46Azacitidine 35Specimen Handling 34Cytarabine 31Biopsy 23fludarabine 22Cyclophosphamide 18decitabine and cedazuridine drug combination 14Injections 14Daunorubicin 14fludarabine phosphate 12Whole-Body Irradiation 11Busulfan 11Mycophenolic Acid 10Melphalan 10Tacrolimus 9Idarubicin 9CPX-351 9ivosidenib 8Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Gemtuzumab 7Decitabine 7Cyclosporine 7enasidenib 6X-Rays 6Magnetic Resonance Spectroscopy 6Filgrastim 6gilteritinib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × iadademstat × 30 days × Clear all
NCT06514261 2026-05-13

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

National Cancer Institute (NCI)

Phase 1 Suspended
45 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡